This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Franklin, T. J. Articles by Bruneau, P. Search for Related Content PubMed PubMed Citation Articles by Franklin, T. J. Articles by Bruneau, P.

Glucuronidation Associated with Intrinsic Resistance to Mycophenolic Acid in Human Colorectal Carcinoma Cells

Cancer Research Department, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG England [T. J. F., V. J., G. J.], and Centre de Recherches, Chemin de Vrilly, Zeneca Pharma, 51689 Reims Cedex 2, France [P. P., P. B.]

The in vivo efficacy of the antitumor, immunosuppressive antibiotic mycophenolic acid is known to be limited by its rapid conversion to the biologically inactive 7-O-glucuronide, catalyzed by UDP-glucuronosyl transferase activity, which is widely distributed among normal tissues, including intestinal epithelium. We have found that mycophenolic acid is also converted to its glucuronide by several lines of human colorectal carcinoma cells, including HT29, Lovo, and Colo-205. In contrast, malignant cell lines not of colorectal origin, including EMT6, HeLa, and SKOV3, showed no ability to metabolize mycophenolic acid. The 7-amino derivative of mycophenolic acid was not metabolized by HT29 cells. This compound was less potent than mycophenolic acid versus EMT6 and HeLa cells but showed inhibitory activity against HT29 cells comparable with the parent antibiotic. The rapid metabolism of mycophenolic acid by HT29 cells was associated with a markedly lower sensitivity to both the antiproliferative activity of the drug and to its ability to inhibit GTP synthesis, compared with cells lacking the capacity for significant glucuronidation. After an initial decline in cellular GTP in HT29 cells induced by mycophenolic acid, there was a progressive recovery in GTP over 48 h, accompanying the metabolism of the antibiotic. This recovery process was not observed in EMT6 cells. It is suggested that glucuronosyl transferase activity may occur widely in colorectal cancer cells and could contribute to resistance to drugs that are susceptible to inactivation by glucuronide conjugation.

¹ To whom requests for reprints should be addressed.

Received 7/28/95. Accepted 12/28/95.

This article has been cited by other articles:

				J. Cummings, B. T. Ethell, L. Jardine, G. Boyd, J. S. Macpherson, B. Burchell, J. F. Smyth, and D. I. Jodrell Glucuronidation as a Mechanism of Intrinsic Drug Resistance in Human Colon Cancer: Reversal of Resistance by Food Additives Cancer Res., December 1, 2003; 63(23): 8443 - 8450. [Abstract] [Full Text] [PDF]

				G. P. Basten, Y. Bao, and G. Williamson Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells Carcinogenesis, August 1, 2002; 23(8): 1399 - 1404. [Abstract] [Full Text] [PDF]

				M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half-Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells Cancer Res., December 1, 1999; 59(23): 5938 - 5946. [Abstract] [Full Text] [PDF]

				M. Korecka, D. Nikolic, R. B. van Breemen, and L. M. Shaw The Apparent Inhibition of Inosine Monophosphate Dehydrogenase by Mycophenolic Acid Glucuronide Is Attributable to the Presence of Trace Quantities of Mycophenolic Acid Clin. Chem., July 1, 1999; 45(7): 1047 - 1050. [Abstract] [Full Text] [PDF]

				P. A. Münzel, S. Schmohl, H. Heel, K. Kälberer, B. S. Bock-Hennig, and K. W. Bock Induction of Human UDP Glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-Butylhydroquinone and 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Caco-2 Cells Drug Metab. Dispos., May 1, 1999; 27(5): 569 - 573. [Abstract] [Full Text]

				T. D. Colby, K. Vanderveen, M. D. Strickler, G. D. Markham, and B. M. Goldstein Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design PNAS, March 30, 1999; 96(7): 3531 - 3536. [Abstract] [Full Text] [PDF]

				E. Schutz, M. Shipkova, V. W. Armstrong, E. Wieland, and M. Oellerich Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipients Treated with Mycophenolate Mofetil Clin. Chem., March 1, 1999; 45(3): 419 - 422. [Full Text] [PDF]

				L. M. Shaw, B. Kaplan, and K. L. Brayman Prospective investigations of concentration–clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring Clin. Chem., February 1, 1998; 44(2): 381 - 387. [Abstract] [Full Text] [PDF]

				T. J. Franklin, V. N. Jacobs, G. Jones, and P. Plé Human Colorectal Carcinoma Cells In Vitro as a Means to Assess the Metabolism of Analogs of Mycophenolic Acid Drug Metab. Dispos., March 1, 1997; 25(3): 367 - 370. [Abstract] [Full Text]

				T. Farazi, J. Leichman, T. Harris, M. Cahoon, and L. Hedstrom Isolation and Characterization of Mycophenolic Acid-resistant Mutants of Inosine-5'-monophosphate Dehydrogenase J. Biol. Chem., January 10, 1997; 272(2): 961 - 965. [Abstract] [Full Text] [PDF]